LEXICON PHARMACEUTICALS, INC. (LXRX)

Import this data to Google Sheets with:

=jivedata("LXRX","financials")

Full statements spill as a table. For one cell: =jivedata("LXRX","Revenue") or =jivedata("LXRX","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

LEXICON PHARMACEUTICALS, INC.

LXRX • CIK 0001062822

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash and Cash Equivalents, at Carrying Value	$22,465	$66,656	$34,326	$40,924
Short-term Investments	$147,561	$171,301	$61,904	$149,686
Property, Plant and Equipment, Net	$1,987	$2,484	$1,863	$1,651
Accounts Receivable, after Allowance for Credit Loss, Current	$1,010	$3,473	$2,384	$1,643
Goodwill	$44,543	$44,543	$44,543	$44,543
Preferred Stock, Shares Outstanding	0	0	0	0
Inventory, Net	$381	$231	$281	$1,196
Operating Lease, Right-of-Use Asset	$5,524	$4,832	$7,318	$6,921
Common Stock, Shares, Outstanding	—	—	365,848,216	446,870,629
Other Assets, Current	$5,130	$4,532	$3,000	$3,128
Restricted Cash	—	—	$29,000	$0
Assets, Current	$176,547	$246,193	$101,895	$196,577
Other Assets, Noncurrent	$828	$368	$368	$368
Assets	$229,429	$298,420	$184,987	$250,060
Long-term Debt, Excluding Current Maturities	$99,508	$100,298	$49,408	$51,437
Other Liabilities, Noncurrent	—	$6,924	$7,174	$9,392
Liabilities	$136,319	$152,470	$77,449	$75,535
Accounts Payable, Current	$14,389	$14,801	$3,083	$2,343
Accrued Liabilities, Current	$17,157	$30,447	$13,189	$12,363
Long-term Debt, Current Maturities	—	—	$4,595	$0
Liabilities, Current	$31,546	$45,248	$20,867	$14,706
Preferred Stock, Value, Issued	$0	$0	$0	$0
Common Stock, Value, Issued	$245	$363	$366	$447
Additional Paid in Capital	$1,862,558	$2,117,325	$2,129,912	$2,227,526
Retained Earnings (Accumulated Deficit)	$-1,766,839	$-1,967,242	$-2,017,583	$-2,050,401
Accumulated Other Comprehensive Income (Loss), Net of Tax	$31	$119	$30	$-204
Treasury Stock, Value	$2,885	$4,615	$5,187	$2,843
Stockholders' Equity Attributable to Parent	$93,110	$145,950	$107,538	$174,525
Preferred Stock, Shares Authorized	5,000,000,000	5,000,000,000	5,000,000,000	5,000,000,000
Preferred Stock, Shares Issued	0	2,304,147	2,304,147	2,712,582
Common Stock, Shares Authorized	300,000,000	450,000,000	450,000,000	900,000,000
Common Stock, Shares, Issued	245,792,668	363,020,303	365,848,216	446,870,629
Treasury Stock, Common, Shares	867,973	1,528,008	2,381,939	1,933,747

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss) Attributable to Parent	$-177,119	$-200,403	$-50,341	$-61,116
Net Cash Provided by (Used in) Operating Activities	$-161,897	$-178,780	$-67,851	$-64,988
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$-23,880	$44,191	$-3,330	$-9,440
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$22,465	$66,656	$63,326	$67,527
Depreciation, Depletion and Amortization	$554	$534	$621	$481
Payments to Acquire Property, Plant, and Equipment	$470	$1,031	$0	$0
Share-based Payment Arrangement, Noncash Expense	$14,340	$13,499	$12,517	$12,693
Payments to Acquire Investments	$223,343	$328,747	$139,838	$212,116
Amortization of Debt Issuance Costs and Discounts	$1,774	$1,845	$1,700	$2,110
Proceeds from Sale, Maturity and Collection of Investments	$173,870	$314,400	$252,858	$182,347
Accretion (Amortization) of Discounts and Premiums, Investments	—	$9,305	$3,712	$2,464
Net Cash Provided by (Used in) Investing Activities	$-49,943	$-15,378	$113,020	$-29,769
Other Noncash Income (Expense)	—	$-812	$1,742	$280
Proceeds from Issuance of Common Stock	$138,823	$0	$0	$70,777
Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised	—	$64	$73	$370
Proceeds from Issuance of Convertible Preferred Stock	—	$241,322	$0	$26,548
Payment, Tax Withholding, Share-based Payment Arrangement	—	—	$572	$2,843
Repayments of Debt	—	—	$48,000	$62,261
Proceeds from Issuance of Long-term Debt	—	$0	$0	$0
Proceeds from (Payments for) Other Financing Activities	—	$-1,307	$0	$-2,274
Net Cash Provided by (Used in) Financing Activities	$187,960	$238,349	$-48,499	$85,317
Interest Paid, Excluding Capitalized Interest, Operating Activities	$10,057	$12,919	$8,330	$6,048
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	$0	$0	$3,243	$3,243
Adjustments to Additional Paid in Capital, Warrant Issued	$307	$0	$0	$0
Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction	$250	$0	$0	$0
Conversion of Stock, Amount Converted	—	$115	$0	$0
Increase (Decrease) in Accounts Receivable	$982	$2,463	$-1,089	$-540
Increase (Decrease) in Inventories	$381	$-150	$50	$1,028
Increase (Decrease) in Prepaid Expense and Other Assets	$2,899	$-598	$-1,532	$-598
Increase (Decrease) in Other Operating Assets	$-467	$-1,152	$-757	$-778
Increase (Decrease) in Accounts Payable and Accrued Liabilities	$6,454	$14,801	$-30,222	$-21,649
Lessee, Operating Lease, Liability, to be Paid, Year One	$1,378	$1,220	$1,649	$2,001
Lessee, Operating Lease, Liability, to be Paid, Year Two	$1,220	$865	$1,683	$2,501
Lessee, Operating Lease, Liability, to be Paid, Year Three	$865	$881	$1,718	$2,555
Lessee, Operating Lease, Liability, to be Paid, Year Four	$881	$898	$1,753	$2,608
Lessee, Operating Lease, Liability, to be Paid, Year Five	$898	$914	$1,863	$2,812
Lessee, Operating Lease, Liability, to be Paid, after Year Five	$4,746	$3,832	$2,979	$2,126
Lessee, Operating Lease, Liability, to be Paid	$9,988	$8,610	$11,645	$14,603
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	$3,432	$2,835	$3,411	$3,910
Operating Lease, Liability	$6,556	$5,775	$8,234	$10,693
Operating Lease, Liability, Current	$1,291	$1,175	$1,642	$2,240
Operating Lease, Liability, Noncurrent	$5,265	$4,600	$6,592	$8,453

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("LXRX","financials")

Full statements spill as a table. For one cell: =jivedata("LXRX","Revenue") or =jivedata("LXRX","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.